MiMedx: The Restatement That Rewrote Three Years of Sales

What happened

MiMedx filed its 2016 annual report showing $245.0 million of net sales in March 2017, and it was the last annual report it would file for three years. An SEC subpoena arrived that April asking about revenue recognition and dealings with certain distributors. The company postponed its 2017 results in February 2018 and an audit committee investigation began, and by that June the chief executive and the president had both resigned based in part on what it found. Nasdaq suspended trading in November 2018 and the delisting took effect the following March.

The case, start to finish

The cleanup cost $117.8 million. The revenue actually at issue was $70.4 million.

Three years without an annual report

MiMedx processed donated human placental tissue into wound-care grafts and sold them into hospitals, wound clinics, the Department of Veterans Affairs and a network of independent distributors. It looked like a manufacturer and ran like a sales force. The 2018 figures make the shape plain: $359.1 million of net sales against $36.4 million of cost of sales, an 89.9% gross margin, with $258.5 million of selling, general and administrative expense sitting on top. Seven times as much went into the field as into the factory.

In March 2017 the company filed its annual report for 2016 showing $245.0 million of net sales. It was the last annual report it would file for three years. An SEC subpoena arrived a month later asking about revenue recognition, dealings with certain distributors, internal controls and employment actions. By February 2018 the 2017 results were postponed and an Audit Committee investigation had begun. That June the chief executive and the president both resigned, based in part on what the investigation had found, and a restructuring specialist took over as interim chief executive.

What the revenue had been claiming

Revenue had been recorded when product shipped. The company's own later analysis explains why that was wrong, and it is not a technicality about timing.

Credit limits existed, and were overridden by sales personnel and by members of management. Customers received conflicting messages about payment terms and rights of return. Arrangements sat outside the written contracts. Put those three facts together and you get the sentence that decides the case: at the moment a box left the building, nobody could honestly say the customer was obliged to pay for it. Under the older rules collectibility was therefore not reasonably assured. Under the newer ones the very first test, whether an enforceable contract exists at all, was not met until money actually arrived.

A sale records that somebody owed you money, not that a box left the building. A control that exists on paper and is overridden in practice does not merely fail to prevent a problem; it destroys the evidence that would let anyone bound one afterward.

The strictest defensible basis

The decision that ended the paralysis was to restate on the harshest available basis and apply it to everything. Rather than trying to separate clean distributor arrangements from contaminated ones, which the investigation could not reliably do, MiMedx moved every year onto cash-receipt recognition: revenue counted when the customer paid.

The reason that is right rather than merely dramatic is procedural. A restatement whose scope keeps moving never closes, because auditors cannot sign a population they cannot bound, and Nasdaq's record shows the exact moment the scope widened from a subset of sales to all of them. That widening is what turned a delay into a delisting: trading was suspended in November 2018 and the delisting took effect in March 2019. Collapsing the question to whether the cash arrived converted an unbounded problem into one that could be tested.

It worked. The March 2020 filing carried restated 2016 figures and the first audited 2017 and 2018 statements, with $51.0 million of product shipped and billed as of the end of 2018 carried as no revenue at all. The company got current with the SEC, settled the Commission's claims against it for a $1.5 million civil penalty, and was relisted on Nasdaq in November 2020, almost exactly two years after being suspended. The SEC's litigation against the former officers continued separately.

Where the damage actually landed

The restatement reversed $70.4 million across 2014 to 2016, taking $550.5 million of reported net sales down to $480.1 million, or 12.8%. It was not evenly spread: 2015 lost 18.2% of its reported sales and 2016 only 9.5%.

Now put the cleanup next to it. Investigation and restatement expense was $51.3 million in 2018 and $66.5 million more in 2019, a total of $117.8 million, roughly 1.7 times the revenue at issue. Net sales then fell 16.7% in 2019 to $299.3 million, hurt by the publicity, by insurance coverage moving against the products, and by experienced sales staff leaving. Three years passed with nothing on file.

That ratio is the part to carry away. The misstatement was not what broke the company; finding out was. If you run a business where the sales team can override a credit limit, understand what you are actually buying with that flexibility: not just some bad debt, but the loss of any defensible line between the sales you can stand behind and the ones you cannot. Control overrides are cheap to allow and ruinous to unwind.

Timeline

• March 1, 2017 MiMedx files its 2016 annual report showing $245.0 million of net sales. It is the last annual report the company will file for three years.
• April 2017 An SEC subpoena arrives asking about revenue recognition, dealings with certain distributors, internal accounting controls and employment actions.
• February 20, 2018 The company postpones its 2017 results and 10-K. An Audit Committee investigation begins.
• June 30, 2018 CEO and chairman Parker H. Petit and president/COO William C. Taylor resign, based in part on what the investigation had found. A restructuring specialist from Alvarez & Marsal takes over as interim CEO.
• November 8, 2018 Nasdaq suspends trading; the delisting becomes effective March 8, 2019. In its last progress report the company had told Nasdaq the scope had widened: it now had to re-examine revenue recognition for ALL of its sales, not a subset.
• March 17, 2020 The 2018 Form 10-K lands, carrying restated 2016 figures and the first audited 2017 and 2018 statements. Every year is put on one basis: revenue counted when the customer paid.
• November 4, 2020 Nasdaq relists the stock, almost exactly two years after suspending it.

You're in the owner's chair

Early 2018. Your Audit Committee has found that sales staff and some managers overrode the company's own credit limits, and that distributors were given payment and return terms outside the signed contracts. Revenue was booked on shipment. The 10-K is already late. What do you do?

• Fix the controls going forward, disclose the problem, and leave prior years alone — the cash was mostly collected in the end
• Restate every year onto cash-receipt recognition and accept whatever number falls out
• Restate only the specific distributor arrangements you can prove carried side terms, and leave the rest on shipment

Three years of sales, before and after the restatement

• 2014 as first reported: 118.2 $M net sales
• 2014 restated: 105.3 $M net sales
• 2015 as first reported: 187.3 $M net sales
• 2015 restated: 153.1 $M net sales
• 2016 as first reported: 245 $M net sales
• 2016 restated: 221.7 $M net sales

The filing lists the adjustments precisely: $12.97M, $34.17M and $23.30M, which is $70.4M in total, or 12.8% of the $550.5M originally reported. The damage was not evenly spread: 2015 lost 18.2% of its reported sales, 2016 only 9.5%. Figures from the March 17, 2020 Form 8-K exhibit.

Business model

MiMedx processed donated human placental tissue into wound-care grafts and sold them into hospitals, wound clinics, the Department of Veterans Affairs and a network of independent distributors. It looked like a manufacturer. It ran like a sales force.

Revenue model

Per-graft sales, largely paid for by insurers and government programs. The economics were extraordinary on paper: 2018 net sales of $359.1 million against $36.4 million of cost of sales, an 89.9% gross margin.

Cost structure

Almost nothing in the factory and almost everything in the field. Selling, general and administrative expense was $258.5 million in 2018, seven times cost of sales. Then came the cleanup: $51.3 million of investigation, restatement and related expense in 2018, and $66.5 million more in 2019.

Strategic challenge

Revenue had been recorded when product shipped. The company's own later analysis explains why that was wrong, and it is not a technicality. Credit limits existed but were overridden by sales personnel and by members of management. Customers received conflicting messages about payment terms and rights of return. Arrangements sat outside the written contracts. At the moment a box left the building, nobody could honestly say the customer was obliged to pay for it. So under the old rules collectibility was not reasonably assured, and under the new ones the first test of all (does an enforceable contract exist?) was not met until money actually arrived.

Key decision

Restate on the strictest defensible basis, and apply it to everything. Rather than trying to sort clean distributor arrangements from contaminated ones, which the investigation could not reliably do, MiMedx moved every year onto cash-receipt recognition. That is why the March 2020 announcement puts cash-basis revenue recognition, applied to every year, in its own headline, and why $51.0 million of product shipped and billed as of December 31, 2018 sat on the books as no revenue at all.

What worked

The severity was the point. A restatement whose scope keeps moving never closes; auditors cannot sign a population they cannot bound. By collapsing the question to 'did the cash arrive', MiMedx produced statements someone would attest to, got current with the SEC, settled the Commission's claims against the company for a $1.5 million civil penalty, and was relisted on Nasdaq in November 2020. The SEC's litigation against the former officers continued separately.

What failed

Everything about the pace and the price. Three years passed with no annual report. The $117.8 million spent on investigation and restatement across 2018 and 2019 was roughly 1.7 times the $70.4 million of revenue actually at issue. The cleanup cost far more than the misstatement. Net sales then fell 16.7% in 2019 to $299.3 million, hurt by the publicity, by insurance coverage moving against the products, and by experienced sales staff leaving.

Risk factors

Concentration in independent distributors whose real payment terms the company could not see; incentive compensation tied to shipped volume; credit controls that existed on paper and were overridden in practice; a single accounting question capable of freezing every filing at once; and reimbursement decisions by insurers that can reprice the whole product line without warning.

Lesson summary

Revenue is a claim about a promise, not about a shipment. If you cannot demonstrate that the customer was obliged to pay you at the moment you booked the sale, you have recorded a hope. And note where the damage actually landed: not in the $70.4 million that was reversed, but in the three years of paralysis, the delisting and the $117.8 million it cost to find out. Control overrides are cheap to allow and ruinous to unwind.

Key data

• $550.5M Net sales 2014–2016, as first reported
• $480.1M Net sales 2014–2016, restated
• $70.4M Revenue reversed
• $117.8M Investigation & restatement cost, 2018–2019
• $51.0M Shipped and billed but not revenue, 31 Dec 2018
• $1.5M SEC civil penalty paid by the company
• Mar 2017 – Mar 2020 Time with no annual report on file

Sources & basis

The company here is real and named, and nothing about it was invented to make the story land. The list below is where each fact came from — public filings, court records, published reporting — so you can open a source and check it against the sentence that used it.

1. MiMedx Group, Form 8-K and Exhibit 99.1 press release, March 17, 2020 — '2018 Net Sales of $359.1 million Reflects Revenue Recognition on Cash Basis for all Years', restated 2014–2016 net sales table, $51.0M shipped-and-billed figure View source ↗
2. MiMedx Group, Form 10-K for fiscal 2019 (filed July 6, 2020) — revenue-recognition analysis (overridden credit limits, collectibility not reasonably assured), SEC investigation and $1.5M civil penalty, delisting history, 2019 net sales of $299.3M View source ↗
3. MiMedx Group, Form 8-K, November 7, 2018 — Nasdaq Hearings Panel determination to suspend trading, and the widened restatement scope View source ↗
4. MiMedx Group, Form 8-K, July 2, 2018 — resignations of Parker H. Petit and William C. Taylor effective June 30, 2018 View source ↗
5. MiMedx Group, Form 10-K for fiscal 2020 (filed March 8, 2021) — Nasdaq relisting on November 4, 2020 View source ↗